Professor Dr. Her Royal Highness Princess Chulabhorn Mahidol Presides over the Opening Ceremony of the Center for Biologics Research and Development (CBRD) Building, Chulabhorn Research Institute (CRI)
Professor Dr. Her Royal Highness Princess Chulabhorn Mahidol
Presides over the Opening Ceremony of the Center for Biologics Research and Development (CBRD) Building,
Chulabhorn Research Institute (CRI)
at the CBRD Building, CRI, Lak Si District, Bangkok, on Friday, August 1, 2025
With Her ability and vision to address people’s health issues, Professor Dr. Her Royal Highness Princess Chulabhorn Mahidol, President of the Chulabhorn Research Institute (CRI), recognizes the urgency for Thailand to build capability in drug development to support public health emergencies, including epidemics, and medicine shortage crises, with a major target of enabling all the Thai people to have access to efficient and affordable medicines. Concerned with the issues, Her Royal Highness initiated and laid the foundation to develop and produce standard biologics, in parallel with personnel development with advanced knowledge and expertise, under the Center for Biologics Research and Development (CBRD), CRI. The CBRD is readily equipped with basic infrastructure, technology, and operational system capable of supporting the comprehensive process of biologics development.
On August 1, 2025 at 3.52 p.m., the President of the CRI graciously presided over the opening ceremony of the CBRD Building, CRI, Lak Si District, Bangkok. The ceremony was attended by executives of the Ministry of Public Health and the CRI who collectively paid their respects to Her Royal Highness.
On this occasion, Her Royal Highness granted an audience to Assoc. Prof. Dr. Supanna Techasakul, Vice President for Royal Affairs of the CRI, to humbly present a program to Her Royal Highness. Professor Emeritus Dr. Khunying Mathuros Ruchirawat, Vice President for Research and Academic Affairs of the CRI, reported on the objectives of the construction of the CBRD Building, CRI. Then, Dr Opas Karnkawinpong, Permanent Secretary for Public Health, reported on the cooperation between the Ministry of Public Health and the CRI as well as the CRI’s drug registration.
Afterwards, Her Royal Highness granted an audience to Mr. Somsak Thepsutin, Minister of Public Health, to humbly present the drug registration certificate of the CRI and the Chulabhorn Royal Academy. Her Royal Highness then graciously pushed an electric button to open a curtain revealing the nameplate “Center for Biologics Research and Development, Chulabhorn Research Institute”. Her Royal Highness then watched a video and visited an exhibition as a tribute to Herself, aimed at reflecting Her inspiration and strong commitment to laying the foundation of drug security for the nation and the Thai people. The event was held in the first floor of the CBRD Building.
The CBRD, CRI, was established with the mission to conduct comprehensive R&D and production of biologics, from the lab level to the semi-industrial level, capable of supporting the creation of potentials in research and development of necessary biologics from upstream to downstream production processes, equipped with advanced technology, development for practical use, in parallel with personnel development, including scientists, pharmacists, and engineers in relevant fields, who will constitute a strong force to sustainably drive Thailand’s biologics manufacturing industry. The CBRD will also serve as a center of international cooperation to enhance knowledge on science and technology through networks of leading universities and biologics industries both domestically and internationally.
The CBRD Building, CRI, is located on land totaling 6-0-9.86 rai, at Lak Si intersection, Bangkok. It is three stories high with a total usable area of 7,245 square meters. It consists of the following facilities: offices, biologics production laboratory, quality control laboratory, and storage room with high standards of cleanliness and safety to support the production of active ingredients of biologics. It is also designed to accommodate future expansion of packaging. Moreover, it is an environmentally friendly building, with the selected use of clean solar energy as part of the energy sources in the building. The CBRD is also certified by the Food and Drug Administration, Ministry of Public Health, as a modern pharmaceutical manufacturing facility based on the GMP (Good Manufacturing Practice) standards. This will elevate the country’s drug production to be on par with international standards and foster confidence in drugs with the highest quality and safety for the Thai people.
Her Royal Highness’s vision is inspired by the Royal Initiatives of His Majesty King Bhumibol Adulyadej the Great in the application of science and technology to elevate the Thai people’s quality of life. Since the establishment of the CRI, Her Royal Highness has relentlessly dedicated Herself to the study and research of health science, including study and research based on natural products and Thai herbs, chemical drugs, and expansion of the development of biologics, bringing new hopes to treat present and future serious and emerging diseases. Her Royal Highness also laid the foundation of the comprehensive “Ecosystem of Biologics Development”, including a laboratory for R&D and production of biologics and a center of animal research to test initial efficiency and safety. The Chulabhorn Graduate Institute produces personnel relevant to drug production. The Chulabhorn Hospital focuses on clinical studies. Cooperation has also been sought with networks of international researchers, leading to the establishment of the “Center for Biologics Research and Development” of the CRI at present. With a focus on comprehensive R&D and production of biologics, the Center succeeded in the development of the biosimilar “Monoclonol Antibody trastuzumab” used to treat numerous types of cancer, especially breast cancer. The biosimilar was granted a drug registration license by the Food and Drug Administration, Ministry of Public Health, under the name graciously bestowed by Her Royal Highness as “HERDARA” in 2025. It is Thailand’s first Monoclonol Antibody, of which R&D was conducted by Thai researchers for the Thai people under the leadership of Professor Dr. Her Royal Highness Princess Chulabhorn Mahidol, “The Princess who provides drug security for the nation”. This crucial success mirrors Her Royal Highness’s immeasurable benevolence to the Thai people. It also marks another crucial step to elevate Thailand’s public health standards and improve the Thai people’s quality of life, with access to equal treatment based on security and sustainability.
Public Relations Section
Office of the President
August 1, 2025
Related Posts
Recent Posts
